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Carolyn Chiswick and colleagues should be 
congratulated on their EMPOWaR study in The Lancet 
Diabetes & Endocrinology examining preventive medical 
intervention for improvement of fetal programming 
during pregnancy.1 The objective of this randomised, 
double-blind, placebo-controlled, trial,  was to establish 
whether metformin use led to improvements in 
maternal and fetal outcomes in obese pregnant women 
without diabetes, in particular in birthweight, which the 
investigators used as a surrogate marker for long-term 
adverse oﬀ spring outcome. Pregnant women with a 
BMI of 30 kg/m² or more and without diabetes received 
up to 2500 mg daily of metformin (n=223) or placebo 
(n=226) from 12 to 16 weeks’ gestation until delivery. 
Mean birthweight at delivery did not diﬀ er between the 
metformin group (3462 g [SD 548]) and the placebo 
group (3463 g [660]). The primary outcome of Z score 
of birthweight percentiles for babies delivered liveborn 
at 24 or more weeks’ gestation and standardised 
for sex, parity and gestation was similar between 
groups and the estimated eﬀ ect size of metformin on 
the primary outcome was non-signiﬁ cant (adjusted 
mean diﬀ erence of –0·029, 95% CI –0·217 to 0·158; 
p=0·7597). Furthermore, metformin had no eﬀ ect on 
prevention of gestational diabetes or maternal weight 
gain compared with placebo.
This well-designed study is one of the ﬁ rst clinical 
trials to investigate preventive treatment in pregnant 
women in hopes of providing protection for the 
unborn child from long-term adverse eﬀ ects later in 
life. The Barker hypothesis conceptualised the notion 
of fetal programming, claiming that the foundation 
for medical disorders encountered in childhood and 
adulthood are planted during fetal life.2 For instance, 
infants that have been exposed to hostile pregnancy 
environments, such as maternal hypertension 
leading to fetal growth restriction, are susceptible 
to developing cardiovascular disease, overt diabetes, 
and hypertension themselves as adults.3 Pregnant 
obese women inherently provide a similarly hostile 
pregnancy environment. These women are at risk 
of excessive gestational weight gain, development 
of gestational diabetes, and hypertension during 
pregnancy, including pre-eclampsia.4 Importantly, 
ﬁ ndings from previous studies have shown higher 
birthweights in oﬀ spring of obese women, which 
have been associated with childhood obesity.5,6 Thus, 
the vicious cycle of maternal obesity passing from 
generation to generation is perpetuated. 
Pregnancy as an opportunity to intervene and break 
this viscous cycle is an appealing option for all health-
care providers in perinatal medicine. The bold idea that 
Future research should investigate the association 
between clinical outcomes and weight gain within 
recommended targets for various BMI groups. Standar -
di sation of reporting of outcomes is required for 
meaningful interpretation of evidence, and clinical 
applicability of ﬁ ndings.
Shakila Thangaratinam 
Women’s Health Research Unit, Barts and the London School of 
Medicine and Dentistry, Queen Mary University of London, 
London E1 2AB , UK
s.thangaratinam@qmul.ac.uk
I am the chief investigator of the National Institute for Health Research project 
HTA–12/01/50 (eﬀ ects of weight management interventions on maternal and 
fetal outcomes in pregnancy: individual patient data [IPD] meta-analysis of 
randomised trials and model-based economic evaluation). The UPBEAT study 
contributes data to the IPD.
Copyright © Thangaratinam. Open Access article distributed under the terms of 
CC BY-NC-ND.
1 Thangaratinam S, Rogozinska E, Jolly K, et al. Eﬀ ects of interventions in 
pregnancy on maternal weight and obstetric outcomes: meta-analysis of 
randomised evidence. BMJ 2012; 344: e2088.
2 Poston L, Bell R, Croker H, et al, on behalf of the UPBEAT Trial Consortium. 
Eﬀ ect of a behavioural intervention in obese pregnant women (the 
UPBEAT study): a multicentre, randomised controlled trial. 
Lancet Diabetes Endocrinol 2015; published online July 10. 
http://dx.doi.org/10.1016/S2213-8587(15)00227-2.
3 Rogozińska E, Chamillard M, Hitman GA, Khan KS, Thangaratinam S. 
Nutritional manipulation for the primary prevention of gestational 
diabetes mellitus: a meta-analysis of randomised studies. PLoS One 2015; 
10: e0115526. 
4 Dodd JM, Turnbull D, McPhee AJ, et al. Antenatal lifestyle advice for women 
who are overweight or obese: LIMIT randomised trial. BMJ 2014; 
348: g1285. 
5 Muktabhant B, Lawrie TA, Lumbiganon P, Laopaiboon M. Diet or exercise, 
or both, for preventing excessive weight gain in pregnancy. 
Cochrane Database Syst Rev 2015; 6: CD007145. 
6 Rasmussen KM, Yatkine AL. Weight gain during pregnancy: reexamining 
the guidelines. Washington: The National Academies Press, 2009. 
7 NICE. Dietary interventions and physical activity interventions for weight 
management before, during and after pregnancy (PH27). London: National 
Institute for Health and Care Excellence, 2010.
Published Online
July 10, 2015
http://dx.doi.org/10.1016/
S2213-8587(15)00234-X
See  Articles page 778
Ve
sn
a A
nd
jic
Metformin and pregnancy outcomes in obese women 
Comment
750 www.thelancet.com/diabetes-endocrinology   Vol 3   October 2015
what we do to the fetus during the short and ﬁ nite 
period of pregnancy could change and even improve 
lifelong outcomes of oﬀ spring validates the whole 
concept of prenatal care. If this concept is true, this 
tiny window of opportunity should not be wasted. 
Pregnancy allows counseling for smoking cessation, 
vaccine administration, and screening for high-risk 
behaviours. 
The idea that metformin administered during 
pregnancy could reduce birthweight in high-risk, 
obese pregnant women is not biologically implausible. 
Animal models, epidemiological studies, and 
systematic reviews suggest that newborn babies with 
high birthweights tend to develop obesity later in 
life.5,6,7 Maternal insulin resistance and hyperglycaemia 
provides a mechanism for excessive neonatal 
birthweight. At this time, metformin, an insulin 
sensitiser, seems to be the best preventive treatment 
for obesity in pregnancy. However, Chiswick and 
colleagues reported no signiﬁ cant diﬀ erences between 
mothers given metformin and those given placebo. 
Various reasons could explain these results. First, 
metformin was initiated late in the ﬁ rst trimester; 
perhaps it would have a greater eﬀ ect if initiated in 
the peri-conceptual period. Common practice is to 
administer metformin before or near the onset of 
conception in women with polycystic ovary syndrome. 
A longer length of treatment, ranging from 8 to 12 
weeks up to 2–3 years, decreases weight over time.8 
A second reason for an absence of diﬀ erence in 
birthweight was the high rate of adverse eﬀ ects on 
treatment adherence. Drug compliance was recorded 
in about two-thirds of patients. However, only 38% 
of patients in the metformin group complied with 
taking the highest dose of 2500 mg per day, and 62% 
complied with the 2000 mg per day regimen. The 
eﬀ ects on weight change are noted at higher doses 
of metformin.8 Thus, perhaps not enough patients 
took the medicine at suﬃ  cient doses to result in a 
signiﬁ cant diﬀ erence in the primary outcome. Finally, 
the greatest diﬀ erence in oﬀ spring weight as a result 
of maternal intervention might happen in childhood, 
rather than the newborn period, as shown in the 
MiG study.9 Follow-up studies are planned for the 
EMPOWaR trial, and the MiG TOFU (The Oﬀ spring 
Follow-Up) study was done at 2 years of age to 
compare body composition in children of women who 
participated in the MiG trial. 
Some data suggested a maternal beneﬁ t from 
metformin. Pregnant women who received metformin 
had a signiﬁ cant reduction in inﬂ ammatory markers 
C-reactive protein and interleukin 6. Additionally, 
fasting plasma glucose and insulin concentrations were 
lower at 28 weeks in women who received metformin 
than in those who received placebo, but these 
diﬀ erences were not maintained at 36 weeks. Although 
changing  glucose homeostasis throughout pregnancy 
might have played a part, poor study drug compliance 
late in gestation is more likely to have contributed 
to this ﬁ nding. At this time, metformin should not 
be used to improve pregnancy outcomes in obese 
women. Although follow-up studies are planned in the 
oﬀ spring, future studies should also focus on potential 
maternal beneﬁ ts from metformin, in both the short 
term and the long term.  
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